Biodistribution of tritiated benzoporphyrin derivative (3H-BPD-MA), a new potent photosensitizer, in normal and tumor-bearing mice.

The biodistribution of a new and very potent photosensitizer, benzoporphyrin derivative-monoacid, ring A (BPD-MA), was determined in normal and P815 (mastocytoma) or M1 (rhabdomyosarcoma) tumor-bearing DBA/2J mice. A dose of 80 micrograms of 3H-BPD-MA was determined at 3, 24, 48, 72, 96 and 168 h post injection. The following tissues were tested: blood, brain, heart, intestine, kidney, lung, liver, muscle, skin, stomach, spleen, thymus and tumor. The biodistribution of 3H-BPD-MA in normal and tumor-bearing mice was comparable overall. 3H-BPD-MA localized in tumors better than in other tissues except kidney, liver and spleen. The tumor to tissue ratios were in the range 1.5-3 at 24 h post injection and increased further during the next 72 h. The highest levels of 3H-BPD-MA were observed in all tissues at 3 h post injection and decreased rapidly during the first 24 h. After 24 h the clearance from tissues was rather slow. The preliminary clearance data obtained in a group of five normal mice indicated that the majority of the injected dose (60%) cleared from the body via the bile and feces, while only about 4% cleared via kidneys and urine. Studies in which 3H-BPD-MA was extracted from tumor, kidney and liver 3 and 24 h after injection showed that, at 3 h, all the photosensitizing activity in tumor was retained. At 24 h only 39% of the activity was retained and considerably less active material was present in liver and kidney.

[1]  T J Dougherty,et al.  Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. , 1975, Journal of the National Cancer Institute.

[2]  T. Dougherty Photodynamic therapy (PDT) of malignant tumors. , 1984, Critical reviews in oncology/hematology.

[3]  J. Kennedy,et al.  Some aspects of porphyrin neurotoxicity in vitro. , 1982, Canadian journal of physiology and pharmacology.

[4]  D. Kessel PROPOSED STRUCTURE OF THE TUMOR‐LOCALIZING FRACTION OF HPD (HEMATOPORPHYRIN DERIVATIVE) , 1986, Photochemistry and photobiology.

[5]  F. Figge,et al.  Cancer Detection and Therapy. Affinity of Neoplastic, Embryonic, and Traumatized Tissues for Porphyrins and Metalloporphyrins.∗ , 1948, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[6]  D. Dolphin,et al.  Preliminary studies on a more effective phototoxic agent than hematoporphyrin. , 1987, Journal of the National Cancer Institute.

[7]  J. Kennedy,et al.  Experimental Porphyric Neuropathy: A Preliminary Report , 1981, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[8]  T J Dougherty,et al.  The structure of the active component of hematoporphyrin derivative. , 1984, Progress in clinical and biological research.

[9]  T. Dougherty,et al.  Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. , 1979, Cancer research.

[10]  A. M. Olsen,et al.  The use of a derivative of hematoporphyrin in tumor detection. , 1961 .

[11]  F. Figge,et al.  Use of hematoporphyrin fluorescence in biliary and cancer surgery. , 1955, The American surgeon.

[12]  D. Kessel,et al.  Probing the structure and stability of the tumor-localizing derivative of hematoporphyrin by reductive cleavage with LiAlH4. , 1987, Cancer research.

[13]  T J Dougherty,et al.  PHOTOSENSITIZERS: THERAPY AND DETECTION OF MALIGNANT TUMORS , 1987, Photochemistry and photobiology.

[14]  T. Dougherty Photosensitization of malignant tumors. , 1986, Seminars in surgical oncology.

[15]  J. Winkelman,et al.  The distribution of tetraphenylporphinesulfonate in the tumor-bearing rat. , 1962, Cancer research.

[16]  J. Levy,et al.  Photoimmunotherapy: treatment of animal tumors with tumor-specific monoclonal antibody-hematoporphyrin conjugates. , 1983, Journal of immunology.

[17]  J. K. Inglis,et al.  Introduction to Laboratory Animal Science and Technology , 1980 .

[18]  M W Berns,et al.  Ability of specific monoclonal antibodies and conventional antisera conjugated to hematoporphyrin to label and kill selected cell lines subsequent to light activation. , 1985, Cancer research.